Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ezetimibe + PegIFN for Chronic Hepatitis D
NCT03105310Phase 2Unknown
- Sponsor
- Aga Khan University
- Start
- Jan 2016
- Primary completion
- Dec 2016
- Modality
- Small Molecules
01
Overview
Phase 2, randomised, open-label trial of ezetimibe in hepatitis D (HDV) (2 arms), sponsored by Aga Khan University. Primary endpoint: Change in HDV RNA quantitative measurements of >2 logs from baseline at 24 weeks. Status: unknown.
02
Drugs
ezetimibe
03
Conditions
hepatitis D (HDV)
Beyond the preview
Go deeper on NCT03105310.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03105310.